Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Meeting Calendar
  3. Past Meetings

ESMO Workshop: Gender Medicine Meets Oncology

ESMO Workshop Gender Medicine Meets Oncology
Start date
30 Nov 2018
End date
01 Dec 2018
Location
Lausanne, Switzerland

Sex differences in efficacy and toxicity of systemic treatments are an undervalued issue in the era of precision oncology1

Gender medicine aims to improve the treatment of women as well as men. During the workshop, this concept, initially developed by cardiologists such as Marianne Legato and Vera Regitz-Zagrosek, will be presented together with examples of sex differences in disease biology and treatment outcomes from various fields of oncology. The theoretical aspects, for example of disease biology and pharmacology, will be reviewed and their implications for the field of oncology will be discussed with a multidisciplinary faculty and audience.

Sex differences in efficacy and toxicity of systemic treatments are an undervalued issue in the era of precision oncology.Gender medicine aims to improve the treatment of women as well as men. During the workshop, this concept, initially developed by cardiologists such as Marianne Legato and Vera Regitz-Zagrosek, will be presented together with examples of sex differences in disease biology and treatment outcomes from various fields of oncology. 

Aims

  • To summarise the differences in chromosomes, hormones, metabolism and the immune system between men and women.
  • To present differences in body composition between men and women, their impact on drug metabolism and differences in the pharmacology of different classes of anti-cancer drugs, as well as possible strategies for dose individualisation.
  • To present differences in disease biology and treatment outcomes in selected types of non sex-related cancers: lymphoma, gastrointestinal cancers and melanoma as examples.
  • To describe how current design and reporting of clinical trials in oncology address a potential impact of the sex of patients on all types of outcomes, as well as methodological hurdles in evaluating the impact of gender in clinical trials.
  • To discuss the consequences of all the above on research and practice in oncology with faculty and audience and elaborate a workshop report and consensus.

View the final programme

Application deadline

Application for the workshop are now closed.

Organising Committee

  • Dorothea Wagner, Lausanne
  • B. Özdemir, Lausanne
  • G-P Dotto, Lausanne

Course venue

Centre Hospitalier Universitaire Vaudois (CHUV),
Rue du Bugnon 46,
1011 Lausanne
Switzerland

1. Özdemir BC et al. Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. J Clin Oncol. 2018 Jul 13:JCO2018783290. doi: 10.1200/JCO.2018.78.3290

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.